Lantern Net Cash Flow from Operations vs Net Cash Flow or Change in Cash and Cash Equivalents Analysis

LTRN Stock

USD 5.97 0.42 6.57%

Trend analysis of Lantern Pharma balance sheet accounts such as Total Stockholder Equity of 34.6 M provides information on Lantern Pharma's total assets, liabilities, and equity, which is the actual value of Lantern Pharma to its prevalent stockholders. By breaking down trends over time using Lantern Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Total Assets Net Tangible Assets

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

About Lantern Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Lantern Pharma at a specified time, usually calculated after every quarter, six months, or one year. Lantern Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Lantern Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Lantern currently owns. An asset can also be divided into two categories, current and non-current.

Lantern Pharma Balance Sheet Chart

Lantern Pharma Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Lantern Pharma uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, Lantern Pharma's Property Plant Equipment is very stable compared to the past year. As of the 16th of April 2024, Other Current Assets is likely to grow to about 1.7 M, while Total Assets are likely to drop about 36.4 M.

Total Assets Other Current Liab Total Current Liabilities Property Plant And Equipment Net Capital Stock

Add Fundamental

Total Assets

Total assets refers to the total amount of Lantern Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Lantern Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Lantern Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Lantern Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.

Capital Stock

The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.

Most indicators from Lantern Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lantern Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lantern Pharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.As of the 16th of April 2024, Selling General Administrative is likely to grow to about 6.3 B, while Issuance Of Capital Stock is likely to drop 0.00.

Lantern Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment	Other Assets	Other Current Assets
Total Assets		0.39	0.92	1.0	0.98	0.79	-0.99	-0.79	0.94	0.99	0.8	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.86	0.39	0.91
Other Current Liab	0.39		0.54	0.38	0.49	0.85	-0.29	-0.84	0.53	0.31	0.22	0.06	0.39	-0.55	0.56	0.72	0.53	0.54	0.38	0.39	-0.54	0.39	-0.55	0.22	-0.32	0.31
Total Current Liabilities	0.92	0.54		0.92	0.95	0.82	-0.85	-0.88	0.98	0.85	0.59	-0.11	0.92	-0.8	0.99	0.92	0.97	1.0	0.92	0.92	-0.8	0.92	-0.8	0.68	0.14	0.87
Total Stockholder Equity	1.0	0.38	0.92		0.98	0.79	-0.99	-0.78	0.94	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.91
Net Tangible Assets	0.98	0.49	0.95	0.98		0.84	-0.94	-0.84	0.97	0.94	0.76	0.02	0.98	-0.89	0.97	0.93	0.99	0.96	0.98	0.98	-0.88	0.98	-0.89	0.81	0.31	0.86
Property Plant And Equipment Net	0.79	0.85	0.82	0.79	0.84		-0.73	-0.93	0.82	0.74	0.67	0.03	0.79	-0.8	0.87	0.94	0.85	0.83	0.79	0.79	-0.78	0.79	-0.8	0.69	0.14	0.64
Net Debt	-0.99	-0.29	-0.85	-0.99	-0.94	-0.73		0.71	-0.89	-1.0	-0.82	-0.07	-0.99	0.89	-0.89	-0.86	-0.93	-0.86	-0.99	-0.99	0.87	-0.99	0.89	-0.88	-0.45	-0.9
Retained Earnings	-0.79	-0.84	-0.88	-0.78	-0.84	-0.93	0.71		-0.89	-0.72	-0.45	-0.08	-0.78	0.85	-0.89	-0.96	-0.88	-0.89	-0.78	-0.79	0.83	-0.78	0.84	-0.51	0.15	-0.76
Accounts Payable	0.94	0.53	0.98	0.94	0.97	0.82	-0.89	-0.89		0.89	0.62	0.08	0.94	-0.87	0.98	0.95	0.99	0.98	0.94	0.95	-0.84	0.94	-0.87	0.69	0.13	0.91
Cash	0.99	0.31	0.85	0.99	0.94	0.74	-1.0	-0.72	0.89		0.82	0.07	0.99	-0.89	0.9	0.87	0.93	0.86	0.99	0.99	-0.88	0.99	-0.89	0.88	0.45	0.9
Non Current Assets Total	0.8	0.22	0.59	0.8	0.76	0.67	-0.82	-0.45	0.62	0.82		0.13	0.8	-0.61	0.69	0.65	0.7	0.6	0.8	0.79	-0.57	0.8	-0.61	0.98	0.79	0.52
Non Currrent Assets Other	0.03	0.06	-0.11	0.03	0.02	0.03	-0.07	-0.08	0.08	0.07	0.13		0.03	-0.18	-0.04	0.06	0.04	-0.09	0.03	0.03	-0.01	0.03	-0.19	0.0	-0.1	0.04
Cash And Short Term Investments	1.0	0.39	0.92	1.0	0.98	0.79	-0.99	-0.78	0.94	0.99	0.8	0.03		-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88	1.0	-0.89	0.87	0.39	0.91
Common Stock Total Equity	-0.89	-0.55	-0.8	-0.89	-0.89	-0.8	0.89	0.85	-0.87	-0.89	-0.61	-0.18	-0.89		-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89	1.0	-0.66	-0.08	-0.86
Common Stock Shares Outstanding	0.95	0.56	0.99	0.95	0.97	0.87	-0.89	-0.89	0.98	0.9	0.69	-0.04	0.95	-0.83		0.95	0.98	0.99	0.95	0.95	-0.82	0.95	-0.83	0.76	0.23	0.87
Capital Surpluse	0.92	0.72	0.92	0.91	0.93	0.94	-0.86	-0.96	0.95	0.87	0.65	0.06	0.91	-0.91	0.95		0.96	0.93	0.91	0.92	-0.9	0.91	-0.91	0.7	0.09	0.86
Other Stockholder Equity	0.97	0.53	0.97	0.97	0.99	0.85	-0.93	-0.88	0.99	0.93	0.7	0.04	0.97	-0.91	0.98	0.96		0.98	0.97	0.97	-0.89	0.97	-0.91	0.76	0.22	0.9
Total Liab	0.93	0.54	1.0	0.92	0.96	0.83	-0.86	-0.89	0.98	0.86	0.6	-0.09	0.93	-0.82	0.99	0.93	0.98		0.92	0.93	-0.82	0.93	-0.82	0.69	0.14	0.88
Net Invested Capital	1.0	0.38	0.92	1.0	0.98	0.79	-0.99	-0.78	0.94	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.92		1.0	-0.88	1.0	-0.89	0.87	0.39	0.91
Total Current Assets	1.0	0.39	0.92	1.0	0.98	0.79	-0.99	-0.79	0.95	0.99	0.79	0.03	1.0	-0.89	0.95	0.92	0.97	0.93	1.0		-0.88	1.0	-0.89	0.86	0.38	0.91
Capital Stock	-0.88	-0.54	-0.8	-0.88	-0.88	-0.78	0.87	0.83	-0.84	-0.88	-0.57	-0.01	-0.88	0.98	-0.82	-0.9	-0.89	-0.82	-0.88	-0.88		-0.88	0.98	-0.65	-0.09	-0.85
Net Working Capital	1.0	0.39	0.92	1.0	0.98	0.79	-0.99	-0.78	0.94	0.99	0.8	0.03	1.0	-0.89	0.95	0.91	0.97	0.93	1.0	1.0	-0.88		-0.89	0.86	0.39	0.91
Common Stock	-0.89	-0.55	-0.8	-0.89	-0.89	-0.8	0.89	0.84	-0.87	-0.89	-0.61	-0.19	-0.89	1.0	-0.83	-0.91	-0.91	-0.82	-0.89	-0.89	0.98	-0.89		-0.66	-0.09	-0.86
Property Plant Equipment	0.86	0.22	0.68	0.87	0.81	0.69	-0.88	-0.51	0.69	0.88	0.98	0.0	0.87	-0.66	0.76	0.7	0.76	0.69	0.87	0.86	-0.65	0.86	-0.66		0.77	0.62
Other Assets	0.39	-0.32	0.14	0.39	0.31	0.14	-0.45	0.15	0.13	0.45	0.79	-0.1	0.39	-0.08	0.23	0.09	0.22	0.14	0.39	0.38	-0.09	0.39	-0.09	0.77		0.09
Other Current Assets	0.91	0.31	0.87	0.91	0.86	0.64	-0.9	-0.76	0.91	0.9	0.52	0.04	0.91	-0.86	0.87	0.86	0.9	0.88	0.91	0.91	-0.85	0.91	-0.86	0.62	0.09

Click cells to compare fundamentals

Lantern Pharma Account Relationship Matchups

Lantern Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Current Liab	489.3K	552.3K	2.2M	2.7M	2.5B	2.6B
Total Current Liabilities	489.3K	552.3K	2.3M	2.8M	2.7M	1.7M
Total Stockholder Equity	943.3K	19.7M	71.6M	56.0M	40.9M	34.6M
Net Tangible Assets	943.0K	19.7M	71.6M	56.0M	64.4M	32.6M
Property Plant And Equipment Net	8.8K	21.5K	216.2K	95.7K	280.4K	294.4K
Net Debt	(1.2M)	(19.1M)	(51.3M)	(37.1M)	(21.7M)	(22.8M)
Retained Earnings	(6.8M)	(12.7M)	(25.0M)	(39.3M)	(55.2M)	(52.5M)
Accounts Payable	489.3K	552.3K	2.2M	2.7M	2.5M	1.6M
Cash	1.2M	19.2M	51.5M	37.2M	21.9M	24.1M
Non Current Assets Total	199.8K	122.7K	1.2M	113.6K	306.3K	363.2K
Cash And Short Term Investments	1.2M	19.2M	70.7M	55.2M	41.3M	34.5M
Common Stock Shares Outstanding	6.3M	6.2M	10.9M	10.9M	10.8M	9.4M
Liabilities And Stockholders Equity	1.4M	20.4M	74.0M	58.8M	43.6M	36.4M
Other Stockholder Equity	7.7M	32.4M	96.7M	95.7M	96.3M	61.0M
Total Liab	489.3K	660.8K	2.4M	2.8M	2.7M	1.8M
Net Invested Capital	929.3K	19.8M	71.6M	56.0M	40.9M	34.7M
Total Current Assets	1.2M	20.2M	72.7M	58.7M	43.3M	36.1M
Capital Stock	25.4K	622.0	1.1K	1.1K	1.1K	1.0K
Net Working Capital	743.5K	19.7M	70.4M	55.9M	40.7M	34.3M
Property Plant Equipment	8.8K	21.5K	216.2K	48.0K	55.2K	65.8K

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lantern Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lantern Pharma's short interest history, or implied volatility extrapolated from Lantern Pharma options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Lantern Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lantern Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lantern Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lantern Pharma Stock:

How To Invest In Lantern

Details

Is Lantern Stock a good investment?

Details

What is Lantern Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in Lantern Stock, please use our How to Invest in Lantern Pharma guide.

You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Lantern Stock analysis

When running Lantern Pharma's price analysis, check to measure Lantern Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lantern Pharma is operating at the current time. Most of Lantern Pharma's value examination focuses on studying past and present price action to predict the probability of Lantern Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lantern Pharma's price. Additionally, you may evaluate how the addition of Lantern Pharma to your portfolios can decrease your overall portfolio volatility.

	Bonds Directory Find actively traded corporate debentures issued by US companies
	AI Investment Finder Use AI to screen and filter profitable investment opportunities
	Fundamental Analysis View fundamental data based on most recent published financial statements
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Equity Valuation Check real value of public entities based on technical and fundamental data

Is Lantern Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lantern Pharma. If investors know Lantern will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lantern Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.47)

Return On Assets

(0.22)

Return On Equity

(0.33)

The market value of Lantern Pharma is measured differently than its book value, which is the value of Lantern that is recorded on the company's balance sheet. Investors also form their own opinion of Lantern Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lantern Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lantern Pharma's market value can be influenced by many factors that don't directly affect Lantern Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lantern Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lantern Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lantern Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lantern Net Cash Flow from Operations vs Net Cash Flow or Change in Cash and Cash Equivalents Analysis

About Lantern Balance Sheet Analysis

Lantern Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Property Plant And Equipment Net

Capital Stock

Lantern Pharma fundamental ratios Correlations

Lantern Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lantern Pharma fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Lantern Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities

Cash	- 1.0	Net Debt
Net Working Capital	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Invested Capital	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity